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Abstract  
Knockout mice lacking the adenosine A2A receptor are less sensitive to nociceptive 
stimuli, and this may be due to the presence of pronociceptive A2A receptors on 
sensory nerves. In support of this hypothesis, we have recently shown that in A2A 
receptor knockout mice there are marked reductions in the changes of two markers of 
spinal cord neuronal activity, [3H]MK801 binding to NMDA receptors and uptake of 
[14C]-2-deoxyglucose, in response to formalin injection.  We now report that 
following a more prolonged inflammatory stimulus, consisting of intraplantar 
injections of PGE2 and paw pressure, there was in contrast an increase in [3H]MK801 
binding and [14C]-2-deoxyglucose uptake in the spinal cords of the A2A receptor 
knockout mice which was much greater than in the wild-type mice.  This increase 
suggests that when there is a pronounced inflammatory component to the stimulus, 
loss of inhibitory A2A receptors on inflammatory cells outweighs the loss of 
pronociceptive A2A receptors on peripheral nerves so that overall there is an increase 
in nociceptive signalling.  This implies that although A2A antagonists have 
antinociceptive effects they may have only limited use as analgesics in chronic 
inflammatory pain.   
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Introduction 
The endogenous purine nucleoside adenosine has complex effects on pain pathways 
which depend on the receptor subtype activated.  It acts through four G protein 
coupled receptors, called A1, A2A, A2B and A3, but at physiological levels of 
adenosine the A1 and A2A receptors are thought to be the most important [9-11] and 
they have opposing effects on pain.  Whereas activation of the A1 receptors has an 
antinociceptive effect, probably through inhibitory A1 receptors in the spinal cord, 
activation of the A2A receptor has a pronociceptive effect, which may be due to the 
presence of these stimulatory receptors on sensory nerves [28, 29].  In support of 
these two opposing actions, mice in which the A1 receptor has been genetically 
deleted (A1 knockout mice) have enhanced nociceptive responses [16], whereas A2A 
knockout mice have reduced responses to thermal nociceptive stimuli [4, 12, 22].  A2A 
knockout mice also have reduced sensitivity to the nociceptive effects of intraplantar 
injection of formalin, with both the initial nociceptive and the delayed inflammatory 
phases of the response being reduced, and this was mimicked by systemic 
administration of the selective A2A antagonist SCH58261 [14].  A similar reduction in 
the hyperalgesic responses to intraplantar injection of another inflammatory stimulus, 
carrageenan, in A2A knockout mice or in wild- type mice locally injected with another 
A2A antagonist, ZM241385, have recently been reported [23].  In this study 
mechanical hyperalgesia was also seen in response to intraplantar injection of an A2A 
receptor agonist, CGS 21680, which was lost in the A2A knockout [23].  These 
findings confirm the pronociceptive effects of A2A receptors in the periphery. 
As well as having altered behavioural responses to nociceptive stimuli, A2A knockout 
mice have altered spinal cord neurochemistry. There is a large reduction in the density 
of the binding of [3H]MK801 to NMDA glutamate receptors and a decrease in the 
uptake of [14C]-2-deoxyglucose (a marker for neuronal activity) in the spinal cord of 
these mice, but no change in the binding to NK1 receptors or AMPA receptors [14, 
15].  There are also changes in spinal cord opioid receptor binding in parallel with 
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changes in the potency of opioid receptor agonists as antinociceptive agents [4].  As 
well as changes in the spinal cords of naïve, unchallenged mice, there is a reduced 
spinal cord response to nociceptive stimulus.  In the wild-type mice intraplantar 
administration of formalin caused a reduced binding of [3H]MK801 to NMDA 
receptors and an increased uptake of [14C]-2-deoxyglucose in the spinal cord, but 
these changes were significantly reduced in the A2A knockout mice [15].  These 
changes in the knockout mice are not likely to be due to loss of A2A receptors in the 
spinal cord itself, as mRNA for the A2A receptor is not expressed in the spinal cord 
[18] and we have been unable to detect A2A receptors there by autoradiographic 
techniques [4].  mRNA for the A2A receptor is present in the dorsal root ganglion, 
although receptors have not been detected there by immunohistochemistry [17, 23], 
suggesting that any receptors expressed may be present at the nerve terminals in the 
periphery.  The changes seen in the spinal cords of A2A knockout mice may therefore 
reflect reductions in nociceptive inputs to the spinal cord caused by the loss of 
pronociceptive peripheral A2A receptors. 
As well as their role in nociceptive pathways, adenosine A2A receptors are also found 
on inflammatory cells including neutrophils, monocytes and macrophages, where 
adenosine plays an inhibitory role and is thought to have an anti-inflammatory effect 
[5].  It seemed possible therefore that knockout of the A2A receptor might in some 
cases enhance responses to nociceptive stimuli rather than reducing them, if there was 
a pronounced inflammatory component.  While the second phase of the response to 
formalin does have an inflammatory component this is a relatively short-lived 
response, so we looked instead at a longer inflammatory stimulus to see if we could 
detect such an enhancement.  We used intraplantar injection of prostaglandin E2 
(PGE2) combined with paw pressure over a period of three hours, and looked at spinal 
cord responses over a 24 hour period.  PGE2 is a pronociceptive inflammatory 
mediator, and peripheral injection of PGE2 causes hyperalgesia that lasts for up to 4 
hours [see 1-3, 20].  In addition, PGE2 can have pro-inflammatory effects, and acting 
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via the EP4 receptor it plays a role in the pathogenesis of rheumatoid arthritis [13, 
24].  Intraplantar PGE2 injection followed by mechanical paw pressure (to test for 
hyperalgesia) has been used as a model for inflammatory pain in rats and mice, 
causing hyperalgeisa, allodynia and oedema lasting for longer than 60 minutes [6, 19, 
26].  It should therefore provide a robust nociceptive stimulus, mimicking a longer-
lasting inflammatory pain condition.  We found that in some regions of the spinal 
cord genetic deletion of the A2A receptor enhanced the responses to this more 
prolonged inflammatory stimulus, in contrast to our previously-reported inhibition of 
the responses to formalin, suggesting that the role of A2A receptors in nociception 
depends on the stimulus.   
Materials and Methods 
Animals.  All animals used in this study were wild-type and A2A knockout male mice 
on a CD1 background [22] aged 8 – 12 weeks bred from heterozygotes at the 
University of Surrey. Animals were age matched throughout with a maximum of one 
week difference between groups of mice used for comparative experiments. All 
experiments described followed protocols agreed by the UK Home Office in 
accordance with the Animals (Scientific Procedures) Act 1985, UK. 
PGE2 injection and mechanical paw pressure.  Mice were designated to one of five 
experimental groupings which corresponded to the time point at which they were to 
be killed. The five groupings were naïve control (before treatment), t=0 (immediately 
after the three hours treatment) and 3, 6 and 24 hours later.  Mice designated to 
treatment groups were lightly restrained before receiving 100ng of PGE2 (Sigma, UK) 
in a volume of 5 µl into the dorsal surface of the left hind paw. PGE2 was dissolved in 
ethanol and further diluted using phosphate-buffered saline so that the amount of 
ethanol injected was less than 1%.  Mice received a total of three injections of PGE2 
into the same paw with a one hour interval between injections. One hour after each 
PGE2 injection and immediately prior to subsequent injection, the injected paw was 
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placed under a pressure bar with a linearly increasing pressure force with a preset 
maximum of 250g (Ugo-Basile analgesymeter modified by Kitchen [21]). At the 
appropriate time points the mice were killed by cervical dislocation and the spinal 
cords removed, frozen in isopentane at -25oC and then stored at -80°C until required 
and processed for receptor autoradiography.  For measurement of [14C]-2-
deoxyglucose uptake the mice received PGE2 injection and mechanical paw pressure 
as above, however 5 minutes before the relevant time point mice were restrained in a 
plastic cylinder, their tails were warmed under a heat lamp and 3700kBq/kg [14C]-2-
deoxyglucose (ARC, USA) was injected intravenously via the tail vein. 20 minute 
later the mice were killed via cervical dislocation and spinal cords were dissected out, 
frozen in isopentane at -25oC and then stored at -80°C until required and processed 
for autoradiography. 
Autoradiographic assessment of [3H]MK801 binding.  20μm thick sections were cut 
from all four anatomical regions of the spinal cord (cervical, thoracic, lumbar and 
sacral) using a crysostat (Microm 505E, Zeiss, UK) maintained at -20°C and thaw-
mounted onto gelatine-coated slides. Adjacent sections were cut for determination of 
total binding and non-specific binding (NSB). Slides with tissue sections were placed 
into storage boxes containing desiccant (Drierite, VWR, UK) for a period of two 
hours at 40C and were then frozen at -200C before use. Sections were pre-incubated in 
50mM Tris buffer (Trizma, Sigma, UK) at pH 7.4 containing 1μM glutamate, 1μM 
glycine and 1μM spermidine for 20 minutes at room temperature. Total binding was 
determined by incubating in the same buffer but with 70nM [3H]-MK801 (Perkin 
Elmer Life Sciences, USA) for 1 hour at 40C, and NSB was determined by the 
addition of 1 mM unlabelled MK801.  Sections were washed for a total of 60 seconds 
in three changes of ice-cold buffer before being briefly rinsed in distilled water and 
then dried in a stream of cool air. Slides were placed into autoradiography cassettes 
(G.E. Healthcare, UK) and apposed for 3 weeks to [3H]-Hyperfilm (GE Healthcare, 
UK) alongside [3H]-microscales of known radioactive concentrations (4048 Bq/mg – 
 7
3.74 Bq/mg, G.E. Healthcare, UK). The resultant autoradiograms were developed in 
Develex developer (Patterson Scientific, UK) for 5 minutes, washed in distilled water 
for 30 seconds and fixed in Amfix (Patterson Scientific, UK) for 4 minutes. Films 
were washed for 30 minutes in distilled water then air-dried prior to analysis. 
Autoradiographic assessment of [14C]-2-deoxyglucose uptake.  20μm thick sections 
were cut from all four anatomical levels of the spinal cord (cervical, thoracic, lumbar 
and sacral) using a crysostat (Microm 505E, Zeiss, UK) and thaw-mounted onto 
gelatine-coated slides. Once dried the slides were apposed to Kodak MR-1 film 
alongside [14C]-microscale standards of known radioactive concentration (31.89kBq/g 
– 1.11kBq/g, G.E. Healthcare, UK). Autoradiographic exposure time was three 
weeks. The resultant autoradiograms were developed in Kodak D-19 developer for 75 
seconds, washed in distilled water containing acetic acid for 30 seconds and fixed in 
Kodak rapid fixer for 3 minutes. Films were washed in distilled water for 30 minutes 
and then air-dried prior to analysis. 
Analysis of autoradiographic images.  Quantitative analysis of spinal cord 
autoradiographic images was performed using an MCID imaging system (Imaging 
Research, Canada) as previously described [14, 15]. For each region of spinal cord 
examined, at least three sections were used for quantification and measurements were 
taken from the whole spinal cord section to improve accuracy and provide a more 
robust comparison between the genotypes.  [3H]MK801 binding was quantified by 
reference to the [3H]-microscale standards and expressed as fmol/mg tissue using the 
calibration provided with the standards. [14C]-2-deoxyglucose uptake was quantified 
by reference to the [14C]-microscale standards and expressed as kBq/g using the 
calibration provided with the standards.  
Data analysis and statistical procedures.  Because of the different control values 
observed between naïve wildtype and adenosine A2A receptor knockout mice reported 
previously [14, 15], data were transformed to generate values as a percentage of 
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control. Statistical analysis was carried out using two-way analysis of variance 
(ANOVA) for factors region and genotype, with post-hoc analysis using Fischer’s 
LSD test where appropriate. One-way ANOVA followed by Dunnett’s post-hoc test 
was carried out on the raw data to identify any differences between control values and 
the data obtained from spinal cords taken from mice 0, 3, 6 and 24 hours following 
PGE2/paw pressure. A probability value of P<0.05 was taken to be significant in all 
cases. 
Results  
We have previously reported a large decrease in [3H]MK801 binding to NMDA 
receptors in all regions of the spinal cords of A2A knockout mice compared to wild-
type controls [14].  In mice treated with PGE2/paw pressure there were no significant 
changes in [3H]MK801 binding in the cervical and thoracic segments in either wild-
type or A2A receptor knockout mice, but there was a significant increase in binding at 
3 hours after treatment in the thoracic and lumbar regions which was greater in the 
A2A knockout mice than in the wild-type (Figure 1, P<0.05, one-way ANOVA with 
Dunnett’s post-hoc test).  Overall there was a significant effect of genotype in the 
lumbar and sacral regions (P<0.05, two-way ANOVA).  
We have also previously reported that the uptake of [14C]-2-deoxyglucose in all 
regions of the spinal cords from A2A receptor knockout mice was significantly 
reduced compared to wild-type mice [15].  In wild-type mice treated with PGE2/paw 
pressure there was no change in [14C]-2-deoxyglucose  uptake in any region of the 
spinal cord, while in A2A receptor knockout mice there was a significant increase in 
[14C]-2-deoxyglucose uptake three hours after treatment in the thoracic region and 
both immediately and three hours after treatment in the lumbar and sacral regions 
(P<0.05, one-way ANOVA with Dunnett’s post-hoc test), with an overall difference 
between genotypes in lumbar and sacral regions (P<0.05, two-way ANOVA) (Figure 
2). 
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Discussion 
The level of restraint required in the mice during the paw pressure procedure 
precluded reliable assessment of nociceptive responses, but the time-dependent 
changes in the spinal cord neurochemical markers that we observed following this 
procedure suggested that it did cause a nociceptive stimulus.  The PGE2/paw pressure 
procedure lasted for three hours, so it represents a more long-lasting inflammatory 
stimulus compared to the formalin procedure used in our previous study [15], in 
which there was a single injection and the nociceptive behaviour only lasted for an 
hour.   
Whereas in the formalin procedure the two markers of spinal cord activity, 
[3H]MK801 binding and [14C]deoxyglucose uptake, were greatly reduced in the A2A 
knockout mice compared to the wild-type [15], when we studied the same markers of 
spinal cord activity in the PGE2/paw pressure model an entirely different pattern of 
responses was observed.  There was an increase in [3H]MK801 binding in the lumbar 
and sacral segments in both wild-type and A2A receptor knockout mice 3 hours after 
the final paw pressure stimulus, 6 hours after the initial PGE2 injection.  As this ligand 
binds to the open channel of the NMDA receptor [8] this may reflect increased 
channel opening, a phenomenon which plays a crucial part in the spinal cord 
sensitisation which is known to occur with prolonged nociceptive stimulation [7, 25].  
This increase was enhanced in the A2A knockout mice, suggesting that in these mice 
there is an increased nociceptive stimulus, in contrast to the results seen with 
formalin.  This apparently paradoxical enhancement probably reflects the role of 
inflammatory cells in the response to PGE2/paw pressure, as the A2A receptor is found 
on many inflammatory cells including neutrophils, monocytes and macrophages, 
where it plays an inhibitory role and is thought to have an anti-inflammatory effect 
[5].  When [14C]-2-deoxyglucose was used as a marker for neuronal activity, there 
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was no change in the wild-type mice but an increase in the lumbar and sacral regions 
both immediately after the end of the stimulus and persisting for three hours in the 
A2A knockout mice.  This increase in [14C]deoxyglucose uptake cannot be attributed 
solely to activation of sensory nerves but reflects increased metabolic activity within 
the spinal cord, which may include activation of descending pathways.  Indeed, it may 
not simply be due to an increase in neuronal firing but may also reflect increased 
metabolic activity in other cell types, or long-term effects such as increased protein 
synthesis.  However, as it was triggered by the PGE2/paw pressure treatment it is 
likely to be a consequence of the inflammatory stimulus applied.  Again, the greater 
response in the A2A knockout mice is likely to reflect the anti-inflammatory role of the 
A2A receptor, so that the genetic loss of this receptor enhances spinal cord activity in 
response to a prolonged inflammatory stimulus rather than decreasing it as in the 
formalin test.  For both the [3H]MK801 binding and the [14C]-2-deoxyglucose uptake 
the changes were more marked in the lumbar and sacral regions than higher up the 
spinal cord, possibly because the PGE” was injected into the hind paw.   
These results are in contrast to the recently-published report showing that the 
hyperalgesic response to injection of carrageenan, was reduced in A2A knockout mice 
[23].  In this study local injection of the A2A antagonist ZM241385 also reduced 
hyperalgesic responses, but only in female mice.  Although carrageenan does cause 
inflammation and in this study there was an increase in paw oedema in both 
genotypes, the primary mechanism of the hyperalgesic response to carageenan is 
chemical stimulation of primary afferents [27].  The reduction in response to 
carrageenan seen in the A2A knockout mice may therefore reflect reduced sensory 
input due to loss of stimulatory receptors on the primary afferents.  We found in the 
formalin test that the time spent licking or biting the injected paw was only 
significantly reduced by knockout of the A2A receptor in the first phase of the 
response, which is largely due to direct stimulation of primary afferents, whereas 
there was no significant reduction in the second phase which has an inflammatory 
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component [14].  When we measured flinches there was a significant reduction in 
both phases in the A2A knockout mice, but it was more marked in the first phase,  This 
again suggests that whereas A2A receptor knockout reduces the activation of primary 
afferents it does not reduce the response to inflammation so effectively.   
 
Conclusions 
Overall, our previous results using [3H]MK801 binding and [14C]-2-deoxyglucose 
uptake after formalin treatment, a short nociceptive stimulus, show reduced changes 
in the spinal cord of A2A knockout mice [15].  This is in agreement with the 
hypothesis that A2A receptors on peripheral nerves enhance nociceptive input into the 
spinal cord, and that this is the likely explanation for the antinociceptive effects of 
A2A antagonists and the reduced nociceptive responses seen in A2A knockout mice [4, 
12, 14, 22].  However, the enhanced neurochemical changes seen in the spinal cord of 
A2A knockout mice after PGE2/paw pressure, a more prolonged inflammatory 
stimulus, implies that in this situation the loss of the A2A receptor on inflammatory 
cells outweighs the loss on peripheral neurones.  The relevance and importance of this 
finding is that although A2A antagonists have antinociceptive effects, they may have 
only limited use as analgesics in chronic inflammatory pain.   
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Figure captions 
Figure 1.  [3H]MK801 binding to NMDA glutamate receptors in spinal cords of 
wildtype and adenosine A2A receptor knockout mice after repeated PGE2 injection and 
mechanical paw pressure (mean ± S.E.M, n=3-7). Measurements were taken from (A) 
cervical, (B) thoracic, (C) lumbar and (D) sacral regions, and expressed as a 
percentage of the values before the first injection of PGE2. Two-way ANOVA 
revealed a significant genotype effect in lumbar and sacral regions (P<0.05). *P<0.05, 
time point vs control. One-way ANOVA followed by Dunnett’s post-hoc test on 
untransformed data to reveal time differences.  
Figure 2.  Uptake of [14C]-2-deoxyglucose ([14C]-2-DG) into spinal cord sections of 
wildtype and adenosine A2A receptor knockout mice after repeated PGE2 injection and 
mechanical paw pressure (mean ± S.E.M, n=3-7). Measurements were taken from (A) 
cervical, (B) thoracic, (C) lumbar and (D) sacral regions, and expressed as a 
percentage of the values before the first injection of PGE2. Two-way ANOVA 
revealed a significant genotype effect in lumbar and sacral regions (P<0.05). *P<0.05, 
time point vs control. One-way ANOVA followed by Dunnett’s post-hoc test on 
untransformed data to reveal time differences.  
 
